Abstract
Subjects and Methods: Seven patients with progressive localized or metastatic chemo-resistant osteosarcoma were treated by gemcitabine.The protocol included gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest. If no progression was observed,maintenance by gemcitabine 1000 mg/m2/w for 3 weeks every 28 days was given until failure was clinically or radiologically evident.
Results. The true objective response rate was 0%. However, disease stabilization and clinical benefit response were observed in five patients (70%) for 13–96 weeks.
Discussion. Postponing the inevitable death with a relatively non-toxic treatment, is, in our opinion, an important issue especially in young patients.Thus it may be justified and warranted to investigate the activity of gemcitabine in a larger group of patients with bone sarcomas.
Full Text
The Full Text of this article is available as a PDF (80.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abratt R. P., Bezwoda W. R., Falkson G., Goedhals L., Hacking D., Rugg T. A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994 Aug;12(8):1535–1540. doi: 10.1200/JCO.1994.12.8.1535. [DOI] [PubMed] [Google Scholar]
- Benjamin R. S., Baker L. H., O'Bryan R. M., Moon T. E., Gottlieb J. A. Chemotherapy for metastic osteosarcoma--studies by the M.D. Anderson Hospital and the Southwest Oncology Group. Cancer Treat Rep. 1978 Feb;62(2):237–238. [PubMed] [Google Scholar]
- Boven E., Schipper H., Erkelens C. A., Hatty S. A., Pinedo H. M. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer. 1993 Jul;68(1):52–56. doi: 10.1038/bjc.1993.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Braakhuis B. J., Ruiz van Haperen V. W., Boven E., Veerman G., Peters G. J. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol. 1995 Aug;22(4 Suppl 11):42–46. [PubMed] [Google Scholar]
- Carmichael J., Fink U., Russell R. C., Spittle M. F., Harris A. L., Spiessi G., Blatter J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996 Jan;73(1):101–105. doi: 10.1038/bjc.1996.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Merimsky O., Meller I., Flusser G., Kollender Y., Issakov J., Weil-Ben-Arush M., Fenig E., Neuman G., Sapir D., Ariad S. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol. 2000;45(2):177–181. doi: 10.1007/s002800050027. [DOI] [PubMed] [Google Scholar]
- Merimsky O., Meller I., Kollender Y., Inbar M. Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer. 1998 Jul;34(8):1296–1297. [PubMed] [Google Scholar]
- Morgan E., Baum E., Bleyer W. A., Movassaghi N., Provisor A., Lampkin B., Lukens J., Griffin T., White H., Fryer C. Treatment of patients with metastatic osteogenic sarcoma: a report from the Children's Cancer Study Group. Cancer Treat Rep. 1984 Apr;68(4):661–664. [PubMed] [Google Scholar]
- Pratt C. B., Champion J. E., Senzer N., Green A. A., Rao B., Douglass E., Meyer W. E., Crom D. B. Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin-doxorubicin. Cancer. 1985 Oct 15;56(8):1930–1933. doi: 10.1002/1097-0142(19851015)56:8<1930::aid-cncr2820560806>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
- Rothenberg M. L., Moore M. J., Cripps M. C., Andersen J. S., Portenoy R. K., Burris H. A., 3rd, Green M. R., Tarassoff P. G., Brown T. D., Casper E. S. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996 Apr;7(4):347–353. doi: 10.1093/oxfordjournals.annonc.a010600. [DOI] [PubMed] [Google Scholar]